Xenetic Bio Share Discussion Threads

[holly_dog] 19/12/2014 11:50

Until they create proper liquidity, proper funds won't invest. So proper valuations go out the window, we are left see sawing on supply / demand and slightly sinister US funds taking advantage.

Ultimately if the science was failing, we'd be toast. The science seems to be progressing well, so that is something to be positive about.

[buywell2] 19/12/2014 11:34

Baxter believes in XEN

It will I believe want to keep XEN afloat going forward as it wants to use its technology


EPO news in 2015 should attract a partner to fund Phase 3 trials


OncoHist news should attract a further inflow of funds from new investors

This still has loads of upside in my opinion

[holly_dog] 19/12/2014 11:29

You can see monthly volume here

hxxp://otce.finra.org/MonthlyShareVolume

[holly_dog] 19/12/2014 11:28

I watch Level 2 most days. From what I understand through that and some chats with Mr M, one of the funds we met to raise funding is more of the 'vulture' variety. Borderline illegal, but with a thinly traded stock such as ours they can manipulate the price down through buying and selling between MMs and then sit on the ask.

On the way down, CANT sat on the bid and CDEL sold down on the ask. For the last 3 weeks they have parked at 25c. Meant to put pressure on the business and try to force a cheap raise. It sounds as though they have been rebuffed, and in the last few days they have been trying to get out. It looked like one of the two finished last night with that last 7.7k, and the other has about 50k left.

We are still massively in limbo with NASDAQ quite a way away, and liquidity is still awful, but it might at least take some short term pressure off. We also have Aus second cohort due before year end and that Aranesp trial in Russia will be great evidence of clinical efficacy against the market leader.

What a frustrating year though eh.

[corrientes] 19/12/2014 10:59

Then he'll have to pull a rabbit out of the hat with one of these umpteen projects.

[ashthorpedo] 19/12/2014 10:56

I got this from Investopedia

Listing requirements for NASDAQ

Listing Requirements for All Companies
Each company must have a minimum of 1,250,000 publicly-traded shares upon listing, excluding those held by officers, directors or any beneficial owners of more then 10% of the company. In addition, the regular bid price at time of listing must be $4, and there must be at least three market makers for the stock. However, a company may qualify under a closing price alternative of $3 or $2 if the company meets varying reequirements. Each listing firm is also required to follow Nasdaq corporate governance rules 4350, 4351 and 4360. Companies must also have at least 450 round lot (100 shares) shareholders, 2,200 total shareholders, or 550 total shareholders with 1.1 million average trading volume over the past 12 months.

Over the past year Xenetic has never had a daily trading volume of 1.1 million shares so if that is the criteria for a NASDAQ listing then it will not happen until 2016 at the earliest.

Or perhaps it is because we don't have 2,200 total shareholders.
A share placing will achieve this but at what price?
At the current price to raise any meaningful amount of capital, shareholders will be massively diluted.
Also raising capital at these prices will also delay any NASDAQ listing as it will take longer to achieve the minimum entry level share price.

[corrientes] 19/12/2014 10:20

and with all these 'dignitaries' on Board. What was the City term in the old days, 'guinea pigs' who were paid a fee to make a Board look respectable and
top class.

The man must live in a dream world.

[ashthorpedo] 19/12/2014 00:32

Scott Maguire is looking like a fool.

The problem we were told was because we were listed in the UK.

Remember this from Proactive Investors 13 June 2012.

He told Proactive Investors the AIM-listed group planned a dual quote "at some point", noting the "huge" value gap that currently exists between the biotechnology sector here and in the US, where it is far better understood and more widely followed.

"When I present at conferences in the US, they think our market cap is five to ten times higher than it actually is and they are quite shocked that it's US$35 million and not US$250/350 million," said Maguire.

So we made the move to the big smoke for a re-rating in January.

Less than 1 year later and the value of the company is US$29.5m and that is after raising $10m.

So it would seem that nothing has changed.

The share price today is worth less than 3.5p old money the lowest it has ever been.

So why does the sophisticated US investors not value us higher?

[corrientes] 18/12/2014 17:30

'Excitement' obviously means different things to different people.

[buywell2] 07/12/2014 11:55

OncoHist looks very promising

[ashthorpedo] 04/12/2014 15:29

I see from the company website that we have new near term milestones

2H14 – Phase 2a Australia progress report on ErepoXen efficacy
 2H14 – ErepoXen Phase 2b Russia interim data on 30 patients
 2H14 – Presentation at ASH on AML by Dana-Farber researcher
 1H15 – U.S. IND filing for AML
 1H15 – U.S. IND filing for an additional OncoHist indication
 1H15 – Initiation of Phase 1/2a study in U.S. of OncoHist in AML and other indication
 1H15 – Initiation of Russia Phase 2 PulmoXen study in cystic fibrosis
 1H15 – Baxter $2M warrant exercise
 2H15 – Receive orphan status in U.S./EU for an additional OncoHist indication

No mention of NASDAQ listing.

[jammytass] 02/12/2014 20:02

Xenetic Biosciences Partner Completes Dosing of Second Cohort in Phase 2a Study of ErepoXen® in Patients with Chronic Kidney Disease on Dialysis
No serious adverse events seen; dosing of third cohort underway with Xenetic Biosciences' proprietary PolyXen® technology for a "bio-better" erythropoietin

LEXINGTON, Mass. (December 2, 2014) - Xenetic Biosciences, Inc. (OTCBB: XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, announces that its license partner and shareholder Serum Institute of India Limited (SIIL) has completed dosing the 10 patients comprising the second cohort of its Phase 2a study with ErepoXen®, a polysialylated form of erythropoietin (EPO).

A total of 20 patients have been dosed to date in this open-label, single escalating dose study underway in India to assess the efficacy, safety and tolerance of ErepoXen in patients with chronic kidney disease who are on dialysis. The third, and a possible fourth cohort, will enroll a further 10 patients each. Follow-up of all patients and data analysis is expected to be completed no later than the end of the third quarter of 2015.

The first cohort of 10 patients received a one-time intravenous dose of 0.5 ug/kg of ErepoXen. This dose was considered to be well tolerated with no drug-related serious adverse events. No clinically relevant or significant abnormalities or trends were observed. The second cohort of 10 patients received a one-time intravenous dose of 1.5 ug/kg of ErepoXen, and these patients too have not exhibited any serious adverse events. Eight of these patients have completed their 28-day follow up. Results from the second cohort are expected to be reported in the first quarter of 2015. Patient enrollment for the third cohort has started. Dependent upon the results from the third cohort, a fourth cohort may or may not have to be enrolled at a higher dose level.

"With this trial for patients on dialysis, ErepoXen is now in clinical trials for a majority of the anemia indications, which have a global market valued in excess of $7B. Relative to other marketed EPOs, our 'bio-better' EPO aims to provide a well-tolerated and effective longer-acting therapy," said M. Scott Maguire, chief executive officer of Xenetic Biosciences. "As the Company generates additional clinical data, we will seek a license partner to take this drug forward in the U.S. and Europe. Clinical data to date has been very encouraging and we look forward to reporting more data this year from our Phase 2a company-sponsored studies in Australia and New Zealand - data which will be submitted to the U.S. Food and Drug Administration. We also expect to report on Phase 2b/3 clinical data from the trials being conducted Russia. We are pleased with the progress our partner Serum Institute of India has been making with its own trials, and the data generated by it in this indication will be very helpful in our own commercialization strategy, as well as providing the potential source of royalty revenues. We look forward to receiving final data from SIIL in 2015."

About ErepoXen

[jammytass] 26/11/2014 20:55

Volume: 100,400 mmmmmmmmmm

[buywell2] 26/11/2014 09:55

Anyone wanting to sell needs to contact the FD

Xenetic have already previously stated that some US funds have enquired about buying shares

A LARGER package of shares could be then put together to sell on

Thus a better price might be obtained














































Xenetic Biosciences Provides Update on Substantial Patent Grants and Allowances in U.S. and Worldwide



Intellectual property covers compounds, methods, uses and multiple geographies with 10 patents recently granted and 13 allowed



LEXINGTON, Mass. (November 25, 2014) – Xenetic Biosciences, Inc. (OTCBB: XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, today provided an update on recent patent grants and allowances worldwide.



Since May 2014, the Company has been issued 10 patents, including six in the U.S., two in Japan and one each in New Zealand and India. In addition, 13 patents have been allowed, including seven in the U.S., two each in Japan and South Korea, and one each in Russia and Canada. Xenetic Biosciences now has over 140 issued patents worldwide and approximately 80 pending patents.



Select key patents issued recently by the U.S. Patent and Trademark Office include Patent No. 8,796,207, Derivatisation of erythropoietin (EPO), which relates to novel polysaccharide derivatives of EPO and methods for producing such derivatives. The derivatives are useful for improving the stability, pharmacokinetics and pharmacodynamics of EPO. This same patent was also issued in Japan during the third quarter.



U.S. Patent No. 8,735,557, Activated sialic acid derivatives for protein derivatisation and conjugation, was also recently granted and relates to polysialic acid and derivatives of polysialic acids which have terminal sialic acid units. This patent covers the targeted conjugation of polysialic acid and its derivatives to therapeutics such as peptides, proteins, drugs, drug delivery systems, etc.



Also issued during the third quarter was U.S. Patent No. 8,828,405, Method to Enhance an Immune Response of Nucleic Acid Vaccination. This patent relates to a composition comprising liposomes associated with a nucleic acid operatively encoding an antigenic protein and with an assistor protein. The composition provides an improved immune response compared with mixtures of liposomes, some of which are associated with the nucleic acid and some of which are associated with the assistor protein.



“Xenetic Biosciences has a substantial patent portfolio to rival any biotech company many times our size. This work results directly from our previous strategy focused on research. Now that we have transformed into a clinical development company, we are well positioned for potentially monetizing our extensive intellectual property portfolio. We expect to add 13 additional patents over the next three months,” said M. Scott Maguire, chief executive officer of Xenetic Biosciences. “We are particularly pleased with our intellectual property position in Japan as those patent grants are typically difficult to secure.

Our IP relates not only to our ‘bio-better217; EPO, our lead candidate, but also to improving availability of a number of protein-based drugs. We recently received an allowance for a U.S. patent relating to novel polysaccharide derivatives of granulocyte colony-stimulating factor (GCSF) and methods for producing such derivatives. The derivatives are useful for improving the stability, pharmacokinetics and pharmacodynamics of GCSF. Our expectations are that we will have strong intellectual property protection for many years after our lead compounds have progressed through the U.S. regulatory process,” Mr. Maguire added.

[jammytass] 25/11/2014 18:56

thats it for a years work file for a few patents maguires havin a laugh

[gregoryan] 25/11/2014 14:52

www.businesswire.com/news/home/20141125005618/en/Xenetic-Biosciences-Update-Substantial-Patent-Grants-Allowances#.VHSW6dKsWSo

[dr biotech] 24/11/2014 15:41

These are just about untradeable. MS trial looks underpowered to me, its not going to give any statistically significant data.

[gregoryan] 23/11/2014 12:45

hxxp://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=104233#.VHHWVZBFBDs

[corrientes] 18/11/2014 22:47

Seems like they are hopeless at managing the company's projects and cash flow. With no control over the timing of these 'milestones' events, its stupid for a tiny company to have fingers in so many pies. Surely as professionals, they'd know that the technical blurb might look good on paper, but it's a sure recipe for disaster.

[heyho2] 18/11/2014 20:03

So when (if ever) is this statement going come true:"In addition to these expected milestones, one of the primary goals of management and the Board is to seek a NASDAQ Capital Market uplist at the earliest practical date"

[heyho2] 18/11/2014 19:40

Thanks Ash,Well that made depressing reading!

[corrientes] 18/11/2014 18:16

Another conman ?